U.S. Vaginal Atrophy Treatment Market Size, Share & Industry Analysis, By Therapy Type (Drug Therapies {Estrogen Based [Imvexxy, Premarin, and Others], Non-Estrogen Based [Intrarosa and Osphena]}), Non Drug Therapies {(Hyaluronic-Acid (HA) Based OTC Solutions [HA Vaginal Suppositories/Inserts, HA Gels & Creams, Others], Others OTC Moisturizers & Lubricants, Light Therapy, Lasers, and Others}), By Route of Administration (Oral, Parenteral, and Topical {Vaginal Inserts / Suppositories, Gels & Creams, & Others}) By Distribution Channel, and Country Forecast, 2026-2034

The U.S. vaginal atrophy treatment market size was valued at USD 1.05 billion in 2025. The market is projected to grow from USD 1.09 billion in 2026 to USD 1.54 billion by 2034, exhibiting a CAGR of 4.34% during the forecast period.

The U.S. market is experiencing steady and significant growth supported by the rising prevalence of vaginal atrophy and increasing awareness around vaginal health and postmenopausal conditions. The country has a well-established healthcare infrastructure and high patient access to gynecological care.

Additionally, the market benefits from the availability of advanced vaginal health hormonal therapies and a wide range of hormonal treatment options with ongoing clinical trials focused on vaginal dryness and related symptoms to enhance quality of life.

• In May 2025, Duchesnay USA partnered with MyMenopauseRx, a virtual doctor's office dedicated to offering high-quality specialists' consultations to expand access to care for women transitioning through menopause.

Many key industry players, such as Pfizer Inc. and Mayne Pharma Group Limited, operating in the market, are focusing on developing various innovative product offerings to support the rising demand for effective vaginal atrophy.

VAGINAL ATROPHY TREATMENT MARKET TRENDS

Rising Strategic Initiatives by Key Industry Players to Boost Adoption is a Key Market Trend

Increasing strategic initiatives by leading industry players to expand their product portfolios and engage in collaborative partnerships is a key trend in the U.S. vaginal atrophy treatment market. These collaborations enable key players to enhance the diagnosis and prescription of drug therapies for the treatment of vaginal atrophy.

• In June 2023, Cosette Pharmaceuticals, a pharmaceutical company offering solutions for women's health and cardiovascular medicines, acquired Intrarosa from Endoceutics. The acquisition aims to accelerate Cosette's women's health portfolio. Intrarosa is available in all markets, including the U.S., U.K., Canada, and others.

Download Free sample to learn more about this report.

MARKET DYNAMICS

MARKET DRIVERS

Innovative Formats for Gels and Lubricants to Drive Market Growth

Innovations in gel and lubricant formats are a key driver for the U.S. vaginal atrophy treatment market growth, offering improved comfort, convenience, and confidence that encourage repeated use and long-term adoption. Conditions such as vaginal atrophy and Genitourinary Syndrome Of Menopause (GSM) that cause symptoms such as dryness, irritation, and painful intercourse, prompting women to seek accessible, immediate relief solutions outside of prescription treatments, especially due to concerns about hormone exposure. These factors have encouraged players to invest and focus on innovative product launches, underscoring the importance as a first line of treatment.

• In August 2023, Good Clean Love developed an Ultra-Hydrating Vaginal Moisturizer with Hyaluronic Acid named Bionourish. This moisturizer was based on an iso-osmolar formula.

MARKET RESTRAINTS

Potential Side Effects Associated with Drug Therapies May Hinder the Growth of Market

The side effects associated with drug therapies reduce long-term adherence or discontinuation of medication, hindering adoption of treatment. Side effects such as itching, burning, or allergic reactions can stop patients from continuing their prescribed therapy, leading to a decline in treatment and consequently restricting the market growth.

• For instance, Pfizer’s Estring (estradiol vaginal system) is commercialized with several warnings, such as Estrogen-alone therapy should not be used for dementia or cardiovascular disease prevention. Additionally, the Women’s Health Initiative (WHI) reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women.

MARKET OPPORTUNITIES

Innovations and Advancements in Treatment Options Offer Lucrative Opportunities

The ongoing innovations and advancements in treatment options present a significant opportunity. The emerging therapy includes hormonal and non-hormonal formulations that have enhanced efficacy and safety profiles, expanding patient acceptance and adherence. The increasing prevalence of menopause-related symptoms and a growing awareness of vaginal atrophy as a distinct medical condition further bolster market demand.

• In October 2025, Bayer received approval from the U.S. FDA for Lynkuet (elinzanetant) 60mg capsules, a dual neurokinin (NK) targeted for the treatment of moderate to severe hot flashes due to menopause.

MARKET CHALLENGES

Social Stigma and Reluctance among Females Regarding Vaginal Disorders Challenges Market Growth

Regardless of the higher prevalence among menopausal women and its impact on quality of life, vaginal atrophy remains a relatively taboo subject in many cultures, leading to a lack of awareness and understanding among women. The stigma surrounding vaginal health issues may prevent women from seeking medical attention or discussing their symptoms openly, resulting in underdiagnoses and under treatment of vaginal atrophy.

• According to the article published by MGH Center for Women's Mental Health in February 2025, more than 1.0 million women go through menopause every year in the U.S. Nearly half of all women above 50 and above experience urinary incontinence. However, two-thirds have not discussed it with their doctor.

Segmentation Analysis

By Therapy Type

Increasing Product Launches for Drug Therapies to Propel Segmental Growth

Based on therapy type, the market is sub-segmented into drug therapies and non-drug therapies.

The drug therapies segment accounted for the largest U.S. vaginal atrophy treatment market share in 2025. Easy accessibility of estrogen-based therapies and non-estrogen therapies for vaginal atrophy treatment drives its dominance. Also, rising regulatory approval and product launches associated with drug therapies are expected to boost the segment’s growth.

• In December 2025, Mayne Pharma Commercial LLC announced that the S. FDA had approved the first generic version of Imvexxy (estradiol vaginal inserts) for the treatment of moderate to severe dyspareunia, which is a symptom of vulvar and vaginal atrophy, caused by menopause.

The non-drug therapies segment is expected to grow at a CAGR of 7.58% over the forecast period. 

To know how our report can help streamline your business, Speak to Analyst

By Route of Administration

Generic Launches and High Efficacy of Topical Drugs Boost Segment’s Growth

Based on route of administration, the market is trifurcated into oral, parenteral, and topical.

The topical segment is expected to account for the largest share of the vaginal atrophy treatment market and held 94.2% of the market in 2025. The dominant share is attributed to its targeted, localized action, and favorable safety profile. Topical therapies such as creams, gels, and vaginal tablets deliver estrogen or non-hormonal agents directly to affected tissues, providing effective symptom relief with minimal systemic absorption. Furthermore, new product approvals for topical drugs are expected to boost the segment’s growth.

• In August 2024, Aurobindo Pharma’s generic estradiol vaginal inserts received the U.S. FDA authorization to be used for the treatment of atrophic vaginitis due to menopause.

The oral segment is expected to grow at a CAGR of 3.08% over the forecast period. 

By Distribution Channel

Wide Product Offering Keeps the Retail Store & Pharmacies Segment at the Leading Position

Based on distribution channel, the segment is divided into hospital pharmacies, retail stores & pharmacies, mass merchandisers, e-commerce & digital platforms, and others.

In 2025, the retail store & pharmacies distribution channel held a dominant share of 40.1%. The segment’s growth is credited to wide product selection and easy access to consumers, making it convenient for women to purchase over-the-counter treatments for Genitourinary Syndrome of Menopause (GSM).

The hospital pharmacies are projected to grow at a CAGR of 3.55% during the study period.

COMPETITIVE LANDSCAPE

Key Industry Players

Strong Market Presence and Offerings to Propel Market Progress

In terms of competitive landscape, the market reflects a fragmented structure comprising several players offering a wide range of products in the market. Pfizer Inc., Mayne Pharma are one of the prominent players with robust product offerings in the drug and non-drug therapies.

• In January 2023, Mayne Pharma Group Limited completed the exclusive product licensing transaction with TherapeuticsMD, Inc. for the commercialization of novel women’s health products: ANNOVERA, IMVEXXY, and BIJUVA.

However, other key players, such as Milicent Pharma and Duchesnay Inc., are expected to engage in market strategies. This includes introduction of new drugs and technologies for the treatment of vaginal atrophy, coupled with the established presence of players with generic products.

LIST OF KEY VAGINAL ATROPHY TREATMENT COMPANIES IN THE U.S.

• Pfizer Inc. (U.S.)
• Mayne Pharma Group Limited (Australia)
• Duchesnay USA (U.S.)
• Church & Dwight Co., Inc. (U.S.)
• Pharmavite LLC (U.S.)
• Novartis AG (Switzerland)
• Novo Nordisk A/S (Denmark)
• Millicent Pharma Ltd. (K.)
• Besins Healthcare (France)
• Good Clean Love (U.S.)
• Laclede, Inc. (U.S.)
• Femallay Inc. (U.S.)
• Fidia Farmaceutici S.p.A. (Italy)
• Joylux, Inc. (U.S.)
• Combe (U.S.)
• Reckitt (U.K.

KEY INDUSTRY DEVELOPMENTS

• November 2025: HITLAB partnered with Cern Corporation, Inc. to advance a non-drug treatment for vaginal infections that leverages low-level microbicidal light and a proprietary photosensitizer-lubricant for women’s health solutions.
• September 2023: LifeMD partnered with women’s health-focused specialty pharmaceutical company ASCEND Therapeutics to improve EstroGel access, a hormone therapy for postmenopausal women.
• September 2023: ASCEND Therapeutics U.S., LLC., in partnership with LifeMD, launched an integrated direct-to-consumer telehealth model for hormone therapy. This launch improved access to EstroGel, a vaginal atrophy product, for a large patient population.
• June 2023: Pfizer Inc. announced the re-entry of DUAVEE (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy in the U.S., with enhanced packaging. DUAVEE has showcased promising results in reducing moderate to severe hot flashes associated with menopause, as well as increasing bone mineral density.
• February 2022: Uqora launched Wash, a cleanser for the vulva. The development expanded the company's product offering in urinary tract health supplements and its UTI relief products.

REPORT COVERAGE

The U.S. vaginal atrophy treatment market research report provides a detailed analysis, focusing on key aspects such as an overview of the market. The report also includes pipeline analysis, by key players, new product launches, and key industry developments. Additionally, it includes information about prevalence of vaginal atrophy in the U.S. and regulatory scenario for non-drug therapies. In addition to these, the report provides insights into market trends and highlights key strategies employed by key players. Furthermore, the report encompasses several other factors that have contributed to the market's growth over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation